Background
Acute lymphoblastic leukemia (ALL) is a leukemia derived from lymphoblasts, primitive progenitor cells originating in the bone marrow. It is most common type of leukemia in children. Patients present with flu-like symptoms, joint pain, and bleeding tendencies with easy bruising. In spite of the ominous diagnosis of leukemia, ALL remains one of the great success stories of oncology. Improvements in chemotherapy and prophylactic treatment as well as insights into the molecular mechanisms have contributed to the advances. In addition, bone marrow transplants provide another treatment option.
OUTLINE
SPECIAL STAINS/
IMMUNOPEROXIDASECHARACTERIZATION L1 and L2 Positive for PAS, acid phosphatase, and +/- for nonspecific esterase and methyl green pyronine L3 Positive for Oil-red-O in cytoplasmic vacuoles and methyl green pyronine
Negative for PAS, acid phosphatease
TdT (Terminal deoxynucleotidyl-transferase) DNA polymerase found in the nuclei of cortical lymphocytes
>90% of T-cell and B-cell precursor ALL are positive Nonpositive Terminal Deoxynucleotidyl Transferase in Pediatric Precursor B-Lymphoblastic Leukemia
Lanting Liu, MD, etal. Am J Clin Pathol 2004;121:810-815 Abstract quote
Terminal deoxynucleotidyl transferase (TdT) is a unique intranuclear DNA polymerase that catalyzes the template-independent addition of deoxynucleotides to the 3'-hydroxyl terminus of oligonucleotide primers. The expression of TdT is restricted to lymphoid precursors. It is a useful marker in distinguishing acute lymphoblastic leukemia (ALL) from mature lymphoid neoplasms. Although TdT– T-cell ALL has been reported in the literature rarely, the frequency and significance of TdT-nonpositive (TdTnp) B-cell ALL have not been examined extensively.
We reviewed the immunophenotypes of 186 new cases of pediatric B-cell ALL and found 5 TdTnp cases (2.7%). They showed significantly higher frequencies of a WBC count of more than 50,000/µL (>50.0 × 109/L), CD10–, CD34–, and MLL gene rearrangement compared with those in TdT+ cases (3/5 [60%] vs 27/181 [14.9%], P = .03; 3/5 [60%] vs 11/181 [6.1%], P = .003; 4/5 [80%] vs 24/179 [13.4%], P = .002; 3/5 [60%] vs 9/181 [5.0%], P = .0019; respectively).
These results indicate that nonpositive TdT does not rule out a diagnosis of ALL and suggest that TdTnp B-cell ALL might be associated with CD10– and CD34– disease, a high WBC count, and MLL gene rearrangement.CD179
Diagnostic importance of CD179a/b as markers of precursor B-cell lymphoblastic lymphoma.
Kiyokawa N, Sekino T, Matsui T, Takenouchi H, Mimori K, Tang WR, Matsui J, Taguchi T, Katagiri YU, Okita H, Matsuo Y, Karasuyama H, Fujimoto J.
Department of Developmental Biology, National Research Institute for Child Health and Development, Japan.
Mod Pathol. 2004 Apr;17(4):423-9.Abstract quote
Surrogate light chains consisting of VpreB (CD179a) and lambda5 (CD179b) are expressed in precursor B cells lacking a complete form of immunoglobulin and are thought to act as substitutes for conventional light chains. Upon differentiation to immature and mature B cells, CD179a/b disappear and are replaced with conventional light chains. Thus, these molecules may be useful as essential markers of precursor B cells.
To examine the expression of the surrogate light-chain components CD179a and CD179b in precursor B-cell lymphoblastic lymphoma, we analyzed tissue sections using immunohistochemistry techniques. Among a number of monoclonal antibodies for the surrogate light chains, VpreB8 and SL11 were found to detect CD179a and CD179b, respectively, in acetone-fixed fresh frozen sections. Moreover, we also observed VpreB8 staining in formalin-fixed, paraffin-embedded sections.
Using these antibodies, we found that CD179a/b were specifically expressed in precursor B-cell lymphoblastic lymphomas, but not in mature B-cell lymphomas in childhood. Furthermore, other pediatric tumors that must be included in a differential diagnosis of precursor B-cell lymphoblastic lymphoma, including precursor T-cell lymphoblastic lymphoma, extramedullary myeloid tumors, and Ewing sarcoma, were also negative for both CD179a and CD179b.
Our data indicate that CD179a and CD179b may be important markers for the immunophenotypic diagnosis of precursor B-cell lymphoblastic lymphomas.MYELOPEROXIDASE Myeloperoxidase Immunoreactivity in Adult Acute Lymphoblastic Leukemia
Daniel A. Arber, MD, David S. Snyder, MD, Miriam Fine, MS, Andrew Dagis, MS, Joyce Niland, PhD, and Marilyn L. Slovak, PhD
Am J Clin Pathol 2001;116:25-33 Abstract quote
To evaluate the frequency and significance of myeloperoxidase positivity in adult acute lymphoblastic leukemia (ALL), bone marrow biopsy material from 82 adults with ALL was evaluated with a polyclonal myeloperoxidase (pMPO) antibody. Nineteen cases (23%) demonstrated evidence of pMPO immunoreactivity. Positive cases were precursor B-cell lineage, and CD13 or CD15 expression was more frequent than in the pMPO-negative cases. A subset of pMPO-positive cases studied with a monoclonal MPO antibody was negative. Western blot analysis using the pMPO antibody showed the expected 55-kd band for myeloperoxidase in pMPO-positive and pMPO-negative ALLs, suggesting a lack of specificity of this antibody in ALL. Forty-two percent (8/19) of the pMPO-positive ALL cases demonstrated evidence of t(9;22) by either karyotype or polymerase chain reaction analysis. The pMPO-positive ALLs had a lower frequency of extramedullary disease than the pMPO-negative group and a trend toward improved overall survival compared with the pMPO-negative group.
Immunoreactivity with pMPO in adult ALL may lead to an incorrect interpretation of biphenotypic acute leukemia using a recently described scoring system, and a revision to that scoring system is proposed to accommodate pMPO-positive ALL.
PODOCALYXIN PodocalyxinA Marker of Blasts in Acute Leukemia
Todd W. Kelley, MD, etal. Am J Clin Pathol 2005;124:134-142 Abstract quote
Podocalyxin is a CD34 family member expressed by podocytes, vascular endothelium, mesothelium, and a subset of hematopoietic progenitors. Podocalyxin expression was not observed in the hematopoietic cells of normal adult bone marrow samples. However, podocalyxin was expressed by blasts in 30 (77%) of 39 cases of acute myeloid leukemia (AML), 22 (81%) of 27 cases of acute lymphoblastic leukemia (ALL), and 13 (87%) of 15 cases of cutaneous myeloid sarcoma.
No correlation with CD34 expression by immunohistochemical analysis was seen. Wilms tumor 1 (WT1) expression was detected in blasts in 17 AML cases (44%) and 21 ALL cases (78%). There was no correlation between WT1 and podocalyxin expression. We conclude that podocalyxin is expressed commonly by blasts in ALL and AML. Analysis of the expression of CD34 and podocalyxin increases sensitivity for the immunophenotypic detection of leukemic blasts compared with the analysis of CD34 alone.
Therefore, podocalyxin seems to complement CD34 as a useful hematopoietic blast marker. The physiologic role of podocalyxin in leukemic blasts remains unknown.
PROGNOSIS AND TREATMENT CHARACTERIZATION Favorable Prognostic Factors Age1-10 years SexFemale RaceWhite WBC<10x10*9/L Rapidity of cytoreductionBone marrow free of disease by day 14 RelapseNo relapse MorphologyLI ImmunophenotypicEarly B-cell precursor
CD10+ (CALLA positive) CytogeneticHyperdiploidy>50 chromosomes Unfavorable Prognostic Factors Age<1 and >10 years SexMale RaceBlack WBC>50x10*9/L Rapidity of cytoreductionResidual disease by day 14 RelapseRelapse MorphologyL2, L3 ImmunophenotypicPre-B-cell (CIg+)
CD10- (CALLA negative)
T-cell ALL
B-cell ALL CytogeneticTranslocations, including t(9;22) and t(4;11) 5 Year Survival B-cell precursor Chemotherapy with CNS prophylaxis and maintenance therapy results in remission in >95% of cases and >50% long-term disease free survival
Postinduction chemotherapy leads to cure rates of 70%
High risk types including T-cell ALL Long term disease free survival of 40-50% Metastasis Relapse occurs in:
Testicles
Brain and spinal cord
Changes that may occur with relapseL1 to L2 morphology
TdT positive to negative
Gain or loss of an antigen
Clonal evolution in 75% with one or more new structural abnormalities
Lineage switch to myeloid leukemia often related to therapy and associated with 11q23 chromosome abnormalityADDITIONAL PROGNOSTIC FACTORS CEREBROSPINAL FLUID
Molecular monitoring of cerebrospinal fluid can predict clinical relapse in acute lymphoblastic leukemia with eosinophilia.Nunez CA, Zipf TF, Roberts WM, Medeiros LJ, Hayes K, Bueso-Ramos CE.
Department of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Arch Pathol Lab Med 2003 May;127(5):601-5 Abstract quote In a patient with precursor B-cell acute lymphoblastic leukemia (ALL) associated with eosinophilia that completely responded to induction chemotherapy, we assayed serial remission cerebrospinal fluid and bone marrow specimens for minimal residual disease using a quantitative polymerase chain reaction assay to assess for clone-specific immunoglobulin heavy-chain gene cluster (IGH) gene rearrangement.
Cerebrospinal fluid eosinophilia and minimal residual disease were detected on day 406, preceding the morphologic diagnosis of central nervous system relapse on day 578. By day 841, the bone marrow had 35% blasts. Despite aggressive therapy, including unrelated umbilical cord blood transplantation, the patient developed testicular and bone marrow relapses and died of disease.
We conclude that increasing levels of minimal residual disease in cerebrospinal fluid can predict recurrence of ALL prior to clinical and morphologic relapse. Furthermore, we demonstrate a novel translocation in this tumor, the t(5;9)(q31;p24), that possibly led to fusion of the interleukin-3 (IL3) (5q31) and JAK2 (9p24) genes and may explain the concomitant appearance of eosinophilia and ALL.
Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia.Howard SC, Gajjar AJ, Cheng C, Kritchevsky SB, Somes GW, Harrison PL, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, De Armendi AJ, Razzouk BI, Pui CH.
Department of Hematology/Oncology, Barry-Longinotti Bldg, Room S2014C, 332 N Lauderdale St, Memphis, TN 38105-2794.
JAMA 2002 Oct 23;288(16):2001-7 Abstract quote CONTEXT: Traumatic or bloody lumbar puncture (LP) reduces the diagnostic value of the procedure and may worsen the outcome of patients with acute lymphoblastic leukemia (ALL). Little is known about the risk factors for traumatic and bloody LP.
OBJECTIVES: To determine the risk factors for traumatic and bloody LP.
DESIGN, SETTING, AND PATIENTS: Retrospective cohort study of 956 consecutive patients with newly diagnosed childhood ALL who were treated at a pediatric cancer center between February 1984 and July 1998.
INTERVENTIONS: All patients underwent a diagnostic LP followed by a median of 4 LPs to instill intrathecal chemotherapy.
MAIN OUTCOME MEASURE: Traumatic LP was defined as an LP in which cerebrospinal fluid contained at least 10 red blood cells (RBCs) per microliter and bloody LP as one in which the cerebrospinal fluid contained at least 500 RBCs per microliter. RESULTS: Of the 5609 LPs evaluated, 1643 (29%) were traumatic and 581 (10%) were bloody. The estimated odds ratios (ORs) and 95% confidence intervals (CIs) for traumatic LP were 1.5 (95% CI, 1.2-1.8) for black vs white race, 2.3 (95% CI, 1.7-3.0) for age younger than 1 year vs 1 year or older, 1.4 (95% CI, 1.2-1.7) for early vs recent (dedicated procedure area and general anesthesia) treatment era, 1.5 (95% CI, 1.2-1.8) for platelet count of 100 x 10(3)/ micro L or more vs less than 100 x 10(3 )/ micro L, 10.8 (95% CI, 7.7-15.2) for short (1 day) vs longer (>15 days) interval since the previous LP, and 1.4 (95% CI, 1.1-1.8) for the least vs the most experienced practitioners. Analyses for bloody LP yielded similar results.
CONCLUSIONS: The unmodifiable risk factors for traumatic and bloody LP include black race, age younger than 1 year, a traumatic or bloody previous LP performed within the past 2 weeks, and a previous LP performed when the platelet count was 50 x 10(3)/ micro L or less. Modifiable risk factors include procedural factors reflected in treatment era, platelet count of 100 x 10(3)/ micro L or less, an interval of 15 days or less between LPs, and a less experienced practitioner.
PHILADELPHIA CHROMOSOME Acute Lymphoblastic Leukemia in Elderly Patients
The Philadelphia Chromosome May Not Be a Significant Adverse Prognostic Factor
Mihaela Onciu, MD
Carlos Bueso-Ramos, MD, PhD
L. Jeffrey Medeiros, MD
Greg Ball, MS
Terry Smith, MS
Raymond Lai, MD, PhDAm J Clin Pathol 2002;117:716-720 Abstract quote
Acute lymphoblastic leukemia (ALL) in elderly patients (59 years or older) carries a poor prognosis, and this finding may be attributed to the relatively high frequency of the Philadelphia chromosome (Ph).To test this hypothesis, we reviewed the clinicopathologic features of 23 consecutive, newly diagnosed elderly patients with ALL (14 men, 9 women, aged 59-92 years) uniformly treated at our institution and compared the Ph+ and Ph groups. Conventional cytogenetic data were available for 21 of 23 cases; 7 (33%) were Ph+. All Ph+ cases were of precursor B-cell type. The remaining 16 tumors were of precursor B-cell (10), mature B-cell (2), precursor T-cell (3), and mixed precursor T-cell/B-cell (1) type. Ph+ and Ph groups did not differ significantly in median survival (13.4 months vs 19.0 months) or other variables studied.
The Ph may not be a significant adverse prognostic factor in ALL in elderly patients.
TREATMENT Combination chemotherapy with CNS prophylaxis and maintenance therapy
Allogeneic bone marrow transplantation following first remission in children with high risk ALL and for relapse following standard chemotherapyHenry JB. Clinical Diagnosis and Management by Laboratory Methods. Twentieth Edition. WB Saunders. 2001.
Rosai J. Ackerman's Surgical Pathology. Ninth Edition. Mosby 2004.
Sternberg S. Diagnostic Surgical Pathology. Fourth Edition. Lipincott Williams and Wilkins 2004.
Robbins Pathologic Basis of Disease. Seventh Edition. WB Saunders 2005.
DeMay RM. The Art and Science of Cytopathology. Volume 1 and 2. ASCP Press. 1996.
Weedon D. Weedon's Skin Pathology Second Edition. Churchill Livingstone. 2002
Fitzpatrick's Dermatology in General Medicine. 5th Edition. McGraw-Hill. 1999.
Weiss SW and Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. Fourth Edition. Mosby 2001.
Basic Principles of Disease
Learn the basic disease classifications of cancers, infections, and inflammation
Commonly Used Terms
This is a glossary of terms often found in a pathology report.Diagnostic Process
Learn how a pathologist makes a diagnosis using a microscopeSurgical Pathology Report
Examine an actual biopsy report to understand what each section meansSpecial Stains
Understand the tools the pathologist utilizes to aid in the diagnosisHow Accurate is My Report?
Pathologists actively oversee every area of the laboratory to ensure your report is accurateGot Path?
Recent teaching cases and lectures presented in conferences
Last Updated July 18, 2005
Send mail to The Doctor's Doctor with questions or comments about this web site.
Read the Medical Disclaimer.
Copyright © The Doctor's Doctor